|
 |
|
|
|
|
|||||
|
Marshall Edwards, Inc. ('MEI') is a pharmaceutical company dedicated to the field of cancer therapy (oncology). MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTR') that reach to the heart of the cancer process. The source of this new range of drugs is a family of chemicals, discovered by pharmaceutical company Novogen, that act against the fundamentals of the cancer process. Using this single technology platform, MEI is developing a number of drugs with novel actions against a range of different cancer types. The first of these drugs - phenoxodiol - has advanced to Phase III clinical studies. Go to Newsroom for the latest announcement and clinical trials for a listing of the current trials. Go to OVATURE trial if you would like more detail on the OVArian TUmor REsponse (OVATURE) Study.  |
140 Wicks Road North Ryde NSW 2113 Australia T: +61 2 8877 6196  |
      
|
| . |
home
: about us.
: about phenoxodiol
: the technology
: newsroom
: Marshall Edwards Inc. 2001 ©
|